Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

PHARBearishLegalnews

High materiality7/10

Pharming declines after revenue downgrade amid ongoing securities investigation

Aug 3, 2026, 10:10 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The combination of a revenue miss, guidance downgrade, and a securities investigation typically worsens sentiment, increases potential litigation costs, and can trigger further downside as investors reassess risk and cash-flow impact; past biotech/pharma cases show sustained volatility until investigations clarify liability and outcomes.

AI summary

What happened, with direct paths to the underlying reporting

Pharming reaffirmed 2026 revenue guidance in May, then slashed the outlook in July to $375–$395 million, triggering a 22% stock drop. Q2 revenue was $90.2 million, down 3% YoY, with RUCONEST sales down 10% to $72.3 million. A securities-law investigation into potential misstatements adds near-term headwinds for PHAR.

Pharming cut 2026 revenue outlook to $375–$395M from $405–$425M; stock fell 22%.
Q2 revenue was $90.2M, down 3% YoY; RUCONEST sales fell 10% to $72.3M.
SueWallSt disclosed pending securities investigation into Pharming and officers.
Investors who bought PHAR may have suffered losses; probe affects price.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Pharming declines after revenue downgrade amid ongoing securities investigation

European Biotech Pharming Group Touts Positive Data From Pivotal Pediatric Study Of FDA-Approved Immune System Disorder Drug